Tyra Biosciences, Inc.
TYRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Tyra Biosciences, Inc. (TYRA) is listed under Biotechnology. The company carries a $1.94B market cap, placing it firmly in the small-cap category. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Market Cap
$1.94B
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
-11.52
EPS (TTM)
$-2.15
EPS (Fwd)
$-2.84
ROE
-36.9%
ROA
-23.6%
Cash
$383.5M
Total Debt
$5.7M
Free CF
-$60.1M
52W Change
259.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $383.5M in cash comfortably exceeding the $5.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$60.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -36.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TYRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.